

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

RECEIVED 1643  
NGV 02 2000

INFORMATION DISCLOSURE STATEMENT

Docket Number  
395/35

TECH CENTER 1600/2300

Application Number  
09/510,562

Filing Date  
February 22, 2000

Examiner  
D. Saunders

Art Unit  
1643

Invention Title  
METHOD OF SCREENING FOR PROTEIN  
INHIBITORS AND ACTIVATORS

Inventor(s)  
Gerard M. HOUSEY

Address to:  
Assistant Commissioner for Patents  
Washington D.C. 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on October 26, 2000.

By:   
Lawrence P. Casson (Reg. No. 46,606)

SIR:


1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97(c) and 1.98 and M.P.E.P. § 609, Applicant hereby brings the references listed on the attached modified PTO Form No. 1449 to the attention of the Examiner. It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The following enclosed references (also listed on the PTO Form 1449) were cited by an opponent in the EPO Opposition Proceedings, or by an Examiner or by third parties during prosecution in the Japanese Patent Office:
  - (1) U.S. Patent No. 4,981,784 (priority for EP 325 849 B1)
  - (2) EP 325 849 B1
  - (3) Fukazawa, H. et al., (1994) FEBS Lett. 340:155-158.
  - (4) Mutschler, E. (1975) Effects of Pharmaceutical Preparations pp. 231-235.
  - (5) Shiroki, K. et al. (1984) J. Virol. 50:854-863.
  - (6) Stryer, L. (1981) Biochemistry pp. 854-855.
  - (7) Uehara, Y. et al. (1989) Biochem. Biophys. Res. Commun. 163:803-809.
  - (8) Yamamoto, K.R. and Alberts, B.M. (1976) Annu. Rev. Biochem. 45:721-746.
3. An English translation is provided for Mutschler, E. (1975) Effects of Pharmaceutical Preparations pp. 231-235.
4. Applicant has previously brought to the Examiners attention documents from the Opposition to EP 0 403 506 B1, which corresponds to this application. Applicant further provides the following:
  - (1) Grounds for Appeal in Opposition to EP 0 403 506 B1 filed in the European Patent Office by Hoechst AG, September 1, 2000.
  - (2) English Translation of Grounds for Appeal in Opposition to EP 0 403 506 B1 filed in the European Patent Office by Hoechst AG, September 1, 2000.
  - (3) Collins Dictionary of the English Language, p 1157 (cited by Hoechst for definition of "presence").

- (4) Grounds for Appeal in Opposition to EP 0 403 506 B1 filed in the European Patent Office by Roche Diagnostics GmbH, August 24, 2000.
- (5) English Translation of Grounds for Appeal in Opposition to EP 0 403 506 B1 filed in the European Patent Office by Roche Diagnostics GmbH, August 24, 2000.
- (6) Grounds for Appeal in Opposition to EP 0 403 506 B1 filed in the European Patent Office by Boehringer Ingelheim GmbH, August 21, 2000.
- (7) English Translation of Grounds for Appeal in Opposition to EP 0 403 506 B1 filed in the European Patent Office by Boehringer Ingelheim GmbH, August 21, 2000.


5. Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office (or in a document submitted to a foreign patent office by a third party) in a counterpart foreign application not more than three months prior to this filing. Accordingly, no fee is believed due. However, should any such fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A duplicate copy of this communication is enclosed.

Dated: October 26, 2000

By:

  
Lawrence P. Casson (Reg. No. 46,606)

KENYON & KENYON  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE STATEMENT**

Docket Number  
395/35

Application Number  
09/510,562

Filing Date  
February 22, 2000

Examiner  
D. Saunders

Art Unit  
1643

Invention Title  
METHOD OF SCREENING FOR PROTEIN  
INHIBITORS AND ACTIVATORS

Inventor(s)  
Gerard M. HOUSEY

Address to:  
Assistant Commissioner for Patents  
Washington D.C. 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on October 26, 2000.

By:   
Lawrence P. Casson (Reg. No. 46,606)

SIR:


1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97(c) and 1.98 and M.P.E.P. § 609, Applicant hereby brings the references listed on the attached modified PTO Form No. 1449 to the attention of the Examiner. It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The following enclosed references (also listed on the PTO Form 1449) were cited by an opponent in the EPO Opposition Proceedings, or by an Examiner or by third parties during prosecution in the Japanese Patent Office:
  - (1) U.S. Patent No. 4,981,784 (priority for EP 325 849 B1)
  - (2) EP 325 849 B1
  - (3) Fukazawa, H. et al., (1994) FEBS Lett. 340:155-158.
  - (4) Mutschler, E. (1975) Effects of Pharmaceutical Preparations pp. 231-235.
  - (5) Shiroki, K. et al. (1984) J. Virol. 50:854-863.
  - (6) Stryer, L. (1981) Biochemistry pp. 854-855.
  - (7) Uehara, Y. et al. (1989) Biochem. Biophys. Res. Commun. 163:803-809.
  - (8) Yamamoto, K.R. and Alberts, B.M. (1976) Annu. Rev. Biochem. 45:721-746.
3. An English translation is provided for Mutschler, E. (1975) Effects of Pharmaceutical Preparations pp. 231-235.
4. Applicant has previously brought to the Examiners attention documents from the Opposition to EP 0 403 506 B1, which corresponds to this application. Applicant further provides the following:
  - (1) Grounds for Appeal in Opposition to EP 0 403 506 B1 filed in the European Patent Office by Hoechst AG, September 1, 2000.
  - (2) English Translation of Grounds for Appeal in Opposition to EP 0 403 506 B1 filed in the European Patent Office by Hoechst AG, September 1, 2000.
  - (3) Collins Dictionary of the English Language, p 1157 (cited by Hoechst for definition of "presence").

- (4) Grounds for Appeal in Opposition to EP 0 403 506 B1 filed in the European Patent Office by Roche Diagnostics GmbH, August 24, 2000.
- (5) English Translation of Grounds for Appeal in Opposition to EP 0 403 506 B1 filed in the European Patent Office by Roche Diagnostics GmbH, August 24, 2000.
- (6) Grounds for Appeal in Opposition to EP 0 403 506 B1 filed in the European Patent Office by Boehringer Ingelheim GmbH, August 21, 2000.
- (7) English Translation of Grounds for Appeal in Opposition to EP 0 403 506 B1 filed in the European Patent Office by Boehringer Ingelheim GmbH, August 21, 2000.

5. Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office (or in a document submitted to a foreign patent office by a third party) in a counterpart foreign application not more than three months prior to this filing. Accordingly, no fee is believed due. However, should any such fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A duplicate copy of this communication is enclosed.

Dated: October 26, 2000

By:



Lawrence P. Casson (Reg. No. 46,606)

KENYON & KENYON  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)